PCN497 A NATIONWIDE COST OF ILLNESS STUDY OF METASTATIC CUTANEOUS MELANOMA IN THE NETHERLANDS.

Authors :: Leeneman, B.
Franken, M.G.
Aarts, M.J.B.
van Akkooi, A.C.J.
van den Berkmortel, F.W.P.J.
van den Eertwegh, A.J.M.
de Groot, J.W.B.
Herbschleb, K.H.
van der Hoeven, J.J.M.
Hospers, G.A.P.
Kapiteijn, E.
Piersma, D.
van Rijn, R.S.
Suijkerbuijk, K.P.M.
ten Tije, A.J.
van der Veldt, A.A.M.
Vreugdenhil, G.
Wouters, M.W.J.M.
Haanen, J.B.A.G.
Uyl-de Groot, C.
Source :: Value in Health. 2019 Supplement 3, Vol. 22, pS534-S534. 1p.
Publication Year :: 2019
Abstract: Novel immunotherapeutic and targeted drugs demonstrated to improve survival of patients with metastatic melanoma. Mean costs were €6,981 (SD: €6,569) for patients who did not receive systemic treatment and €89,335 (SD: €78,749) for patients who did receive systemic treatment. Costs of patients who did not receive systemic treatment were mainly driven by costs of hospital admissions (38%), medical imaging (17%), and surgery (15%), whereas costs of patients who did receive systemic treatment were predominantly driven by drug costs (84%). [Extracted from the article]

Full Text Access

Tools